The purpose of this study is to evaluate the efficacy of Cart 19 cells therapy as measured by overall remission rate, which includes Complete Remission and Complete Remission with incomplete blood count recovery assessment in infants to adults.
The overall goals of this study are to find the best dose of bosutinib that we can give safely, and to find out what effects, good and/or bad, bosutinib has on children and adolescents with Chronic Myeloid Leukemia (CML).
Phase 1 open-label study to estimate the safety, manufacturing feasibility, and efficacy of intravenously administered, lentivirally transduced T cells expressing anti-CD123 in pediatric subjects with relapsed/refractory Acute Myeloid Leukemia.
The Teachey Lab studies perturbations in leukemic cell signal transduction pathways with the aim of identifying targeted cancer inhibitors and immunotherapies that can treat children with high-risk leukemias and autoimmune lymphoproliferative syndrome.
This phase 1/2 study will determine the safety, feasibility, and efficacy of CD33 CART cells following lymphodepleting chemotherapy in patients with acute myeloid leukemia (AML).
The Felix Lab aims to understand the pathobiology of leukemias with KMT2A (MLL) translocations in order to discover better treatments and preventative approaches.
